<- Go Home
TenX Keane Acquisition
As of August 12, 2024, TenX Keane Acquisition was acquired by Citius Oncology, Inc., in a reverse merger transaction. TenX Keane Acquisition does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. TenX Keane Acquisition was incorporated in 2021 and is based in New York, New York.
Market Cap
$269.4M
Volume
29.1K
Cash and Equivalents
$261.00
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$49.00
52 Week Low
$9.54
Dividend
N/A
Price / Book Value
-88.64
Price / Earnings
164.91
Price / Tangible Book Value
-88.64
Enterprise Value
$272.0M
Enterprise Value / EBITDA
N/A
Operating Income
-$1.3M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$261.00
Debt
$2.6M
Equity
-$3.0M
Revenue
N/A
Unlevered FCF
N/A
Sector
Capital Markets
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium